{
  "docId": "019de514-c6ee-70fe-9ed1-115332e66453",
  "docSlug": "7d8148a830366811cd98c46e453c2fa7",
  "documentTitle": "Adagio Therapeutics | Investor Conference Presentation Deck | 10 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Invivyd",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 10,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "propose_solution",
  "function": "propose_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de514-c6ee-70fe-9ed1-115332e66453/5",
  "deckHref": "/decks/019de514-c6ee-70fe-9ed1-115332e66453",
  "deckJsonHref": "/decks/019de514-c6ee-70fe-9ed1-115332e66453.json",
  "deckAnchorHref": "/decks/019de514-c6ee-70fe-9ed1-115332e66453#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.48,
        "w": 0.305,
        "x": 0.62,
        "y": 0.305
      },
      "kind": "image",
      "text": null,
      "attrs": {},
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "00c56637-fbeb-4dec-9298-cefe74143885",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.54,
        "x": 0.045,
        "y": 0.773
      },
      "kind": "list",
      "text": "NVD200 shows in vitro neutralizing activity against: Pre-Omicron VOCs,\nOmicron variants BA.1, BA.2, BA.4, BA4.6 BA.5, BA.2.75, and SARS-CoV-2.",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "61a36a01-3b06-467e-9967-24ff0c42fa8e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.43,
        "w": 0.45,
        "x": 0.045,
        "y": 0.32
      },
      "kind": "list",
      "text": "Designed for:\nHigh potency\nLack of polyreactivity\nLong half-life\nDevelopability\nPatient and health system ease of use\nPotential to resist escape\nTarget non-overlapping epitopes of spike RBD\nRare epitopes under less immune pressure\nConserved across human ACE2-using sarbecoviruses",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bed7d851-b45e-4f44-867b-4cabf002b539",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.022,
        "w": 0.34,
        "x": 0.045,
        "y": 0.87
      },
      "kind": "list",
      "text": "Phase 1 trial start planned Q1 2023",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cff3d582-7d3a-473b-891d-01c4b2bc634c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.022,
        "w": 0.43,
        "x": 0.045,
        "y": 0.262
      },
      "kind": "paragraph",
      "text": "NVD200 = VYD224 + VYD222 (Re-engineered ADG20)",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eca779d5-b685-4eae-a961-8f5ef5ce7046",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.16,
        "x": 0.045,
        "y": 0.915
      },
      "kind": "source-note",
      "text": "RBD, receptor binding domain\nVOC, variant of concern",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "562df937-9294-4786-a316-c5e6a71e71fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.099,
        "w": 0.73,
        "x": 0.045,
        "y": 0.076
      },
      "kind": "title",
      "text": "NVD200: A COMBINATION APPROACH OF TWO ANTIBODIES TARGETING DISTINCT EPITOPES",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f0f97b7-0cec-4d3d-a20d-58108e843dd8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "f6419657-7b14-4721-a09e-ffed3c7b38c8",
      "evidence": "list/bullet: Designed for: High potency",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 5,
      "beatId": "8f586047-fdbe-4793-9641-0c1f5c37eadc",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The presentation of Invivyd's combination approach and pipeline of antibodies",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 5,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "82a8193a-fe63-44e6-9054-8fee1a4a2720",
      "evidence": "The discussion of the challenge of rapidly evolving variants and the need for adaptable treatments",
      "position": 0,
      "objective": "What is the cost of not having effective treatments for COVID-19?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 7,
      "from": 5,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "ebd5e9d0-7739-45d1-9c72-3cc4af38795c",
      "evidence": "The presentation of Invivyd's combination approach and pipeline of antibodies",
      "position": 1,
      "objective": "Why is Invivyd's approach effective in developing COVID-19 product candidates?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}